

FURTHER READING

FURTHER READING

Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. *J Urol* 1993; 150 (6): 1837-9. DeAntoni EP , Crawford ED, Oesterling JE et al. Age- and race - specific reference ranges for prostate-specific antigen from a large community-based study . *Urology* 1996; 48 (2): 234-9. European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator. Available from [http://www . prostatecancer-riskcalculator.com/seven-prostate-cancer -risk - calculators](http://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators). Hamdy FC, Donovan JL, Lane JA et al . 10-year outcomes after monitoring, surgery , or radiotherapy for localized prostate cancer. *N Engl J Med* 2016; 375 (15): 1415-24. Kaisary A V , Ballaro A, Pigott K. *Urology: lecture notes* , 7th edn. Hoboken, NJ: Wiley-Blackwell, 2016. McAninch JW , Lue TF . *Smith & T anagho's general urology* , 18th edn. New Y ork: Lange, 2012. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. *JAMA* 1993; 270 (7): 860-4. Prostate Cancer Prevention Trial Risk Calculator V ersion 2.0. Available from <https://riskcalc.org/PCPTRC/>. Wein AJ, Kavoussi LR, Partin AW , Peters CA. *Campbell-Walsh urology* , 12th edn. Amsterdam: Elsevier, 2020.

Revision #1

Created 2025-12-31 15:29:30 UTC by Omar Ayman

Updated 2025-12-31 15:29:30 UTC by Omar Ayman